Abcentra
- Biotech or pharma, therapeutic R&D
Abcentra is a clinical-stage therapeutics company with a focus in cardiovascular disease, and a highly-differentiated first-in-class drug candidate that is about to enter phase 2b for an indication in acute coronary syndrome secondary prevention. The Company recently closed a $50M financing round, which funds the company through the phase 2b data readout milestone.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}